A few people have contacted me about Kadcyla. Whilst I have a full diary on the 26th January, I will attempt to attend as much of the debate as I can.
I do appreciate the concern about this issue, and I am aware that the National Institute for Health and Care Excellence (NICE) is currently updating its guidance on the use of Kadcyla as a treatment for secondary breast cancer.
I know that people with cancer place great importance on drugs that can increase their life expectancy, and therefore NICE applies as much flexibility as it can when looking at new life-extending treatments. Unfortunately, NICE has previously found that the price being charged for Kadcyla by the pharmaceutical company which manufacturers it was too high in relation to the benefits it gives for it to be recommended for routine commissioning in the NHS.
Draft updated NICE guidance on Kadcyla has been published for consultation and NICE's final guidance is expected in March. Kadcyla will continue to be available through the Cancer Drugs Fund while the NICE appraisal is ongoing.

Email Newsletter Signup


Follow Me